Marker Therapeutics Ergebnis für das dritte Quartal 2023: 0,34 US$ Verlust pro Aktie (gegenüber 0,83 US$ Verlust im 3. Quartal 2022) - Simply Wall St News
![Marker Therapeutics, Inc. on X: "Marker's new cGMP manufacturing facility in Houston is where we manufacture our MultiTAA-specific T #celltherapies for our Phase 2 trial in #AML. Learn more about Marker's #immunotherapy Marker Therapeutics, Inc. on X: "Marker's new cGMP manufacturing facility in Houston is where we manufacture our MultiTAA-specific T #celltherapies for our Phase 2 trial in #AML. Learn more about Marker's #immunotherapy](https://pbs.twimg.com/media/E_W08k5WEAg-06k.jpg)
Marker Therapeutics, Inc. on X: "Marker's new cGMP manufacturing facility in Houston is where we manufacture our MultiTAA-specific T #celltherapies for our Phase 2 trial in #AML. Learn more about Marker's #immunotherapy
![Marker Therapeutics, Inc. on X: "Marker's CMO Dr. Mythili Koneru will be on the panel “Building on Success – Clinical and Commercial Dynamics in Heme Malignancies and Hematopoietic Transplantation” at @CelloHealth's Cancer Marker Therapeutics, Inc. on X: "Marker's CMO Dr. Mythili Koneru will be on the panel “Building on Success – Clinical and Commercial Dynamics in Heme Malignancies and Hematopoietic Transplantation” at @CelloHealth's Cancer](https://pbs.twimg.com/media/FP0mUQgWQAIY5Pd.jpg:large)